Health Care & Life Sciences » Pharmaceuticals | Ceres Ventures Inc.

Ceres Ventures Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2007
2008
2009
2010
2011
Cost of Goods Sold (COGS) incl. D&A
9.50
348.60
263.10
-
-
Gross Income
9.50
348.60
263.10
-
-
SG&A Expense
2,075.40
887.30
253.90
428.20
570.50
EBIT
2,084.90
1,478.20
588.20
428.20
570.50
Unusual Expense
-
20.00
41.80
15.00
-
Non Operating Income/Expense
-
14.80
-
2,566.00
-
Interest Expense
105.50
70.40
63.80
95.90
1.10
Pretax Income
2,155.40
1,560.80
693.80
2,027.70
571.60
Consolidated Net Income
2,155.40
1,560.80
693.80
2,027.70
571.60
Net Income
2,155.40
1,560.80
693.80
2,027.70
571.60
Net Income After Extraordinaries
2,155.40
1,560.80
693.80
2,027.70
571.60
Net Income Available to Common
2,155.40
1,560.80
693.80
2,027.70
571.60
EPS (Basic)
0.50
0.50
0.00
0.50
0.01
Basic Shares Outstanding
3,850.30
4,008.00
4,013.50
4,525.10
68,465.70
EPS (Diluted)
0.56
0.39
0.17
0.30
0.01
Diluted Shares Outstanding
3,850.30
4,008.00
4,013.50
6,806.20
68,465.70
EBITDA
2,075.40
1,476.20
588.20
428.20
570.50
Other Operating Expense
-
242.30
71.30
-
-
Non-Operating Interest Income
35.00
22.70
-
0.80
-

About Ceres Ventures

View Profile
Address
430 Park Avenue
New York New York 10022
United States
Employees -
Website -
Updated 07/08/2019
Develops novel clean technologies for the remediation and purification of water, air, and soil .